Active, not recruitingPhase 2NCT03787680

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Studying Twin-reversed arterial perfusion sequence

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Michigan Rogel Cancer Center
Principal Investigator
Zachery Reichert, M.D., MD
University of Michigan Rogel Cancer Center
Intervention
Olaparib(drug)
Enrollment
49 target
Eligibility
18 years · MALE
Timeline
20192028

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03787680 on ClinicalTrials.gov

Other trials for Twin-reversed arterial perfusion sequence

Additional recruiting or active studies for the same condition.

See all trials for Twin-reversed arterial perfusion sequence

← Back to all trials